EQS-Adhoc

LifeWatch AG: Main offer period of BioTelemetry, Inc.'s tender offer for LifeWatch AG shares begins

EQS Group-Ad-hoc: LifeWatch AG / Key word(s): Offer LifeWatch AG: Main offer period of BioTelemetry, Inc.'s tender offer for LifeWatch AG shares begins 10-May-2017 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR Main offer period of BioTelemetry, Inc.'s tender offer for LifeWatch AG shares begins Zug/Switzerland, May 10, 2017 - LifeWatch AG (SIX Swiss Exchange: LIFE), a leading developer and provider of medical solutions and remote diagnostic monitoring services in the digital health market, announced that the main offer period of BioTelemetry, Inc.'s (NASDAQ: BEAT) tender offer starts today and will remain open for a period of ten (10) trading days. The offer is scheduled to expire at 4:00 p.m. CEST, on May 23, 2017. The settlement of the tender offer is subject to regulatory approvals and other customary conditions. As previously stated in the report of the LifeWatch Board of Directors, the Board fully supports the public tender offer by BioTelemetry and recommends that shareholders accept it and tender their shares accordingly. BioTelemetry's offer provides shareholders two choices. The shareholders of LifeWatch agreeing to tender their shares can choose to receive either CHF 10.00 in cash and 0.1457 shares of BioTelemetry stock (Main Offer Consideration) (equivalent to CHF 4.00 per LifeWatch share based on the closing price of BioTelemetry on Friday, April 7, 2017) or CHF 8.00 in cash and 0.2185 shares of BioTelemetry stock (Alternative Offer Consideration) (equivalent to CHF 6.00 per LifeWatch share based on the closing price of BioTelemetry on Friday April 7, 2017), depending on individual shareholder preference. Taking into consideration the closing price of BioTelemetry's stock on May 9, 2017, the Main Offer Consideration and the Alternative Offer Consideration now have values of CHF 14.34 or CHF 14.51, respectively. The increase in BioTelemetry's stock price since the initial announcement on April 9, 2017 has increased the total deal value to a range of CHF 265 million to CHF 268 million from the initial value of CHF 259 million at April 7, 2017.